FY2018 · ended Dec 31, 2018 · Revenue $500,000 · Filed Mar 23, 2020
DiaMedica Therapeutics Inc. (DMAC) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$29.1 million. As of Jun 30, 2026 it held $43.5 million in cash and investments and $185,000 in total debt.
Revenue
$500,000
Net income
$-32.77M
-34.0% vs prior year
Operating cash flow (TTM)
$-31.51M
-22.8% vs year-ago TTM
Free cash flow (TTM)
$-31.54M
-22.8% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
53.88M
+25.7% vs prior year
Net cash
$43.32M
as of Jun 30, 2026
Operating margin
-1352.2%
FY 2018
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DMAC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Minneapolis, MN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1401040
- Former names
- DiaMedica Inc. (until Mar 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$34.4M | -$26.7M | -$21.3M | -$14.0M | -$13.6M |
| Net income | -$32.8M | -$24.4M | -$19.4M | -$13.7M | -$13.6M |
| Operating cash flow | -$29.1M | -$22.1M | -$18.7M | -$11.5M | -$12.3M |
| Free cash flow | -$29.1M | -$22.1M | -$18.8M | -$11.6M | -$12.3M |
| Total assets | $61.4M | $46.3M | $54.2M | $34.4M | $45.6M |
| Stockholders' equity | $56.1M | $40.7M | $51.1M | $31.8M | $44.0M |
| Cash and investments | $59.9M | $44.1M | $52.9M | $33.5M | $45.1M |
| Total debt | $240,000 | $340,000 | $400,000 | $469,000 | $90,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 21, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| ARS | Annual report to shareholders | Apr 1, 2026 | Dec 31, 2025 |
All 427 DiaMedica Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.